Blake Kaufmann

Blake Kaufmann

Associate

Mergers & Acquisitions

San Francisco

blake.kaufmann@wsgr.com

D415-947-2402

Download vCard

Open PDF

Blake Kaufmann is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he focuses primarily on mergers & acquisitions. He advises both public and private clients in mergers, tender offers, stock purchases, asset acquisitions, and other strategic corporate transactions.

Experience

Education

J.D., University of Pennsylvania Law School, 2024
Editor, Penn Law Journal of Law and Innovation
B.A., Double Major in Economics and Political Science, University of California, Los Angeles, 2020

Admissions

State Bar of California

Credentials

Education

J.D., University of Pennsylvania Law School, 2024
Editor, Penn Law Journal of Law and Innovation
B.A., Double Major in Economics and Political Science, University of California, Los Angeles, 2020

Admissions

State Bar of California

Recent Insights

Client Highlights

On August 4, 2026, DISA® Technologies, a uranium recovery and production company, announced the formation of DISA Uranium™ Corporation, a new American company built to recover and produce domestic uranium and remediate the nation's legacy uranium sites. In connection with its launch, DISA Uranium has entered into a definitive agreement to acquire IsoEnergy's Utah uranium portfolio of permitted, past-producing mines and projects—giving DISA Uranium a scaled conventional resource base to pair with its proprietary processing technology and the only U.S. Nuclear Regulatory Commission license of its kind. Wilson Sonsini Goodrich & Rosati advised DISA on the transaction.

Learn More

Client Highlights

On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.

Learn More